Table 1. Clinical and Molecular Characteristics of the 83 GBM Patients*.
| Clinical or MolecularFeature | Cases | ||
| No. | % | ||
| Total No. of patients | 83 | ||
| Sex | |||
| Male | 50 | 60.2 | |
| Female | 33 | 39.8 | |
| Age, years | |||
| Mean | 56.7 | ||
| SD | 17.8 | ||
| ≥60 | 40 | 48.2 | |
| <60 | 43 | 51.8 | |
| KPS | |||
| Mean | 78.7 | ||
| SD | 12.4 | ||
| Tumor size, cm3 | |||
| Mean | 66.8 | ||
| SD | 24.2 | ||
| Extent of resection | |||
| Gross total resection | 38 | 45.8% | |
| Residual tumor <30% | 20 | 24.1% | |
| Residual tumor >30% | 25 | 30.1% | |
| MGMT promoter | |||
| Methylated | 25 | 30.1% | |
| Unmethylated | 58 | 69.9% | |
| Plasma IGFBP-2, ng/ml | |||
| Mean | 637.0 | ||
| SD | 52.3 | ||
| Median | 627.5 | ||
*KPS: Karnofsky performance status; IGFBP-2: Insulin-like growth factor binding protein 2; MGMT: O(6)-methylguanine-DNA-methyltransferase.